Molecular Neuroscience and Gene Therapy Group

2021 | Adriana Marcelo, Rebekah Koppenol, Luís Pereira de Almeida, Carlos A. Matos, Clévio Nóbrega. Stress granules, RNA-binding proteins and Polyglutamine diseases: too much aggregation? Cell Death and Disease, 12: 592.

2021 | Afonso-Reis R, Afonso IT, Clévio Nóbrega. Current Status of Gene Therapy Research in Polyglutamine Spinocerebellar Ataxias. International Journal of Molecular Sciences, 22: 4249. PMID: 33921915

2020 | Clévio Nóbrega, Liliana Mendonça, Carlos A. Matos. A Handbook of Gene and Cell Therapy. Springer. ISBN 978-3-030-41332-3.

2019 | Clévio Nóbrega, Mendonça L, Adriana Marcelo, Antonin Lamazière, Sandra Tomé, Gaëtan Déspres, Carlos A. Matos, Fatich Mechmet, Dominique Langui, Wilfred den Dunnen, Luis Pereira de Almeida, Nathalie Cartier and Sandro Alves. Restoring brain cholesterol turnover improves autophagy and has therapeutic potential in mouse models of spinocerebellar ataxia. Acta Neuropathol. 138:837-58. PMID: 31197505.

2019 | Nunes C, Mestre I, Marcelo A, Koppenol R, Matos CA, Clévio Nóbrega. MSGP: the first database of the protein components of the mammalian stress granules. Database (Oxford), baz031. PMID: 30820574.

2019 | Mendonça L, Clévio Nóbrega, Tavino S, Brinkhaus M, Matos CA, Tomé S, Moreira R, Henriques D, Kaspar BK, de Almeida LP. Ibuprofen enhances synaptic function and neural progenitor’s proliferation markers and improves neuropathology and motor coordination in Machado-Joseph disease models. Hum. Mol. Genet., 28:3691-3703. Q1, PMID: 31127937.

2019 | Clévio Nóbrega, Codêsso JM, Mendonça L, Pereira de Almeida L. RNAi therapy for Machado-Joseph disease: long-term safety profile of lentiviral vectors enconding shRNAs targeting mutant ataxin-3. Hum Gene Ther., 30: 841-54. PMID: 30760052. Citações: 9.

2019 | Marcelo A, Brito F, Carmo-Silva S, Matos CA, Alves-Cruzeiro J, Vasconcelos-Ferreira A, Koppenol R, Mendonça L, Almeida LP, Clévio Nóbrega. Cordycepin activates autophagy through AMPK phosphorylation to reduce abnormalities in Machado-Joseph disease models. Hum. Mol. Genet., 28:51-63.  Q1, IF= 5.119. PMID: 30219871.

2019 | Matos CA, Pereira de Almeida L, Clévio Nóbrega. Machado-Joseph disease/spinocerebellar ataxia type 3: lessons from disease pathogenesis and clues into therapy. J Neurochem, 148: 8-28. PMID: 29959858.

2018 | Oliveira Miranda C, Marcelo A, Silva TP, Barat J, Vasconcelos-Ferreira, Pereira D, Clévio Nóbrega, Duarte S, Barros I, Alves J, Sereno J, Petrella LI, Castelhano J, Paiva, VH, Rodrigues-Santos P, Alves V, Nunes-Correia I, Nobre RJ, Castelo-Branco M, Pereira de Almeida, L. Repeated Mesenchymal Stromal Cell Treatment Sustainably Alleviates Machado-Joseph disease. Mol. Ther. 26:2131-2151. Q1, IF= 7.970. PMID: 30087083. Citações: 10.

Project: Development of novel molecular therapies for Cockayne syndrome
Period of execution: May 2021 – Present
Coordinator: Clévio Nóbrega
Funding agency: Fundação privada

---

Project: The role of stress granules in Polyglutamine disease: from pathogenesis to molecular therapy
Period of execution: October 2018 – Present
Coordinator: Clévio Nóbrega
Funding agency: Fundação para a Ciência e Tecnologia (FCT); PTDC/MED-NEU/29480/2017

---

Project: Overexpression of the RNA-binding protein G3BP1 as a therapeutic strategy to Machado-Joseph disease and other Polyglutamine diseases
Period of execution: March 2019 – Present
Coordinator: Clévio Nóbrega
Funding agency: The French Muscular Dystrophy Association (AFM – Téléthon)

2021 | Ideias em Caixa – Prémio de Empreendedorismo na área da Saúde e Bem Estar CRIA – UAlg PolyQure, to Clévio Nóbrega

2020 | Prémio da Sociedade Portuguesa de Genética Humana, to Clévio Nóbrega

2018 | Janssen Innovation Award (2nd edition): Ataxin-2 as a key regulator of hypothalamic metabolic function (2nd place), Janssen, to Clévio Nóbrega

2017 | Young Scientist Lectureship Award, European Neurochemistry Society, to Clévio Nóbrega

2016 | Prémio da Sociedade Portuguesa de Genética Humana, to Clévio Nóbrega